Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 3
1993 4
1994 3
1995 2
1996 4
1997 1
1998 6
1999 6
2000 4
2001 4
2002 12
2003 8
2004 7
2005 11
2006 11
2007 6
2008 11
2009 16
2010 16
2011 20
2012 27
2013 19
2014 24
2015 19
2016 18
2017 22
2018 26
2019 25
2020 24
2021 33
2022 24
2023 16
2024 13
2025 11
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean choffski p[au] (1,735 results)?
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.
Garralda E, Schöffski P, Oberoi A, Schuler M, Richly H, Ascierto PA, Lin CC, Álvarez R, Patel SP, Xing Y, Subbiah V, Lewis N, Patel S, Wang-L-Akshman L, Lee JB, Hassounah NB, Lee LH, Roy M, Banerjee S, Reynolds A, Koyama T, Shimizu T. Garralda E, et al. Among authors: schoffski p. Eur J Cancer. 2026 Jun 24;244:116899. doi: 10.1016/j.ejca.2026.116899. Online ahead of print. Eur J Cancer. 2026. PMID: 42407248
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.
Zemp FJ, Breckenridge Z, Song H, Gill GS, Louie TL, Narta K, Liu H, Suh Y, Guignard L, Mandujano-Tinoco EA, Collao N, Pyczek J, Ellestad KK, Curry J, Langley J, John C, Mah LK, Rajwani J, Evseev D, Turk M, Benaoudia S, Alex J, Naumenko V, Manoharan VT, Mehrabadi MK, Smith HA, Gilbert GNY, Gillmor A, Verhey TB, Todesco HM, Osz K, Ahn BY, Bogossian A, Anderson C, Sikdar S, Rukunuddin S, Bismar TA, Heng DYC, Lawson K, Linehan WM, Pedersen H, Gordon PMK, McIntyre JB, MacGregor J, Garzia L, Brodeur-Robb K, DiFrancesco L, Ogilvie T, Schöffski P, Wozniak A, Holt RA, Bell J, Senger DL, Lewis V, Monument M, Khan O, Baudrier L, Billon P, Gabriel V, Biernaskie J, Potts K, Trpkov K, Hay K, Quizi J, Chan J, Saleh R, Henning JW, Prokopishyn NL, Shafey M, Morrissy AS, Mahoney DJ. Zemp FJ, et al. Among authors: schoffski p. Nat Cancer. 2026 Jul 1. doi: 10.1038/s43018-026-01194-3. Online ahead of print. Nat Cancer. 2026. PMID: 42387022
Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.
Khosroyani HM, Teuber A, Town A, Klug LR, Evans D, Call J, Rothschild S, Somaiah N, Thirasastr P, Liu M, Chi P, Hohenberger P, Rutkowski P, Schöffski P, Agaimy A, Brahmi M, Killian JK, Frampton GM, Beadling C, Bauer S, Falkenhorst J, Heinrich MC. Khosroyani HM, et al. Among authors: schoffski p. Cancer Res Commun. 2026 Jul 1;6(7):1573-1591. doi: 10.1158/2767-9764.CRC-26-0093. Cancer Res Commun. 2026. PMID: 42275235 Free PMC article.
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.
Schöffski P, Sanfilippo R, Martín-Broto J, Kawai A, Desai J, LoRusso P, Maki RG, Jones RL, Blay JY, Smrke A, Abdul Razak A, Italiano A, Sebio A, Bahleda R, Lee YC, van der Graaf WTA, Zhang X, Biyukov T, Teufel M, Fu E, Lahmar M, Wagner AJ. Schöffski P, et al. Clin Cancer Res. 2026 Jun 10. doi: 10.1158/1078-0432.CCR-26-0509. Online ahead of print. Clin Cancer Res. 2026. PMID: 42268294
Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.
Ratan R, Kasper B, Alcindor T, Schöffski P, van der Graaf WT, Federman N, Bui NQ, D'Amato G, Riedel RF, Attia S, Chawla S, Lim A, Tumminello B, Oton AB, Chu Y, Zhou S, Gounder M. Ratan R, et al. Among authors: schoffski p. J Clin Oncol. 2026 Apr 24:JCO2600107. doi: 10.1200/JCO-26-00107. Online ahead of print. J Clin Oncol. 2026. PMID: 42030530 No abstract available.
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.
Rohrberg KS, Lopez JS, Milhem MM, Blank CU, Reijers I, Thistlethwaite F, Plummer R, Piha-Paul SA, Jänne PA, Shum E, Shaw HM, Debruyne PR, Lao C, Baurain JF, Choe JH, Gort E, Zhao Y, Jerusalem G, Schöffski P, Chen AW, Cohen EA, Mankowski WC, Roshkovan L, Katz SI, Kontos D, Brady LK, Qutaish M, Castro PG, Pencheva N, Bajaj G, Fu Y, Windfeld K, Reiter P, Jure-Kunkel M, Higgs BW, Amiri KI, Ahmadi T, Forssmann U, Ramalingam SS, Vergote I. Rohrberg KS, et al. Among authors: schoffski p. Cancer Res Commun. 2025 Nov 1;5(11):2066-2078. doi: 10.1158/2767-9764.CRC-25-0359. Cancer Res Commun. 2025. PMID: 41166388 Free PMC article. Clinical Trial.
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.
Ratan R, Kasper B, Alcindor T, Schöffski P, van der Graaf WTA, Federman N, Bui NQ, D'Amato G, Riedel RF, Attia S, Chawla S, Lim A, Tumminello B, Oton AB, Chu Y, Zhou S, Gounder M. Ratan R, et al. Among authors: schoffski p. J Clin Oncol. 2025 Dec;43(34):3646-3651. doi: 10.1200/JCO-25-00582. Epub 2025 Oct 20. J Clin Oncol. 2025. PMID: 41115259 Free PMC article. Clinical Trial.
411 results